Reply: Infantile Leigh-like syndrome caused by SLC19A3 mutations is a treatable disease

Brain

Volumn 137, Issue 9, 2014, Pages

  Gerards, Mike ^a,b,c   De Coo, René ^d   Smeets, Hubert ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; MEMBRANE PROTEIN; SLC19A3 PROTEIN; THIAMINE; UNCLASSIFIED DRUG;

BRAIN DISEASE; DISEASE COURSE; GANGLION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LEIGH DISEASE; LETTER; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPLEMENTATION;

EXOME; FEMALE; HUMANS; LEIGH DISEASE; MALE; MEMBRANE TRANSPORT PROTEINS;

EID: 84906705372     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu129     Document Type: Letter

References (12)

1. Alfadhel M, Almuntashri M, Jadah RH, Bashiri FA, Al Rifai MT, Al Shalaan H, et al. Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J Rare Dis 2013; 8: 83.
2. Debs R, Depienne C, Rastetter A, Bellanger A, Degos B, Galanaud D, et al. Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. Arch Neurol 2010; 67: 126-30.
3. Distelmaier F, Huppke P, Pieperhoff P, Amunts K, Schaper J, Morava E, et al. Biotin-responsive basal ganglia disease: a treatable differential diagnosis of leigh syndrome. JIMD Rep 2013; doi:10.1007/8904-2013-271.
4. Fassone E, Wedatilake Y, DeVile CJ, Chong WK, Carr LJ, Rahman S. Treatable Leigh-like encephalopathy presenting in adolescence. BMJ Case Rep 2013; 2013: 200838.
5. Gerards M, Kamps R, van Oevelen J, Boesten I, Jongen E, de Koning B, et al. Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome. Brain 2013; 136 (Pt 3): 882-90.
6. Haack TB, Klee D, Strom TM, Mayatepek E, Meitinger T, Prokisch H, et al. Infantile Leigh-like syndrome caused by SLC19A3 mutations is a treatable disease. Brain 2014; doi:10.1093/brain/awu128.
7. Kevelam SH, Bugiani M, Salomons GS, Feigenbaum A, Blaser S, Prasad C, et al. Exome sequencing reveals mutated SLC19A3 in patients with an early-infantile, lethal encephalopathy. Brain 2013; 136 (Pt 5): 1534-43.
8. Kono S, Miyajima H, Yoshida K, Togawa A, Shirakawa K, Suzuki H. Mutations in a thiamine-transporter gene and Wernicke's-like encephalopathy. N Engl J Med 2009; 360: 1792-4.
9. Perez-Duenas B, Serrano M, Rebollo M, Muchart J, Gargallo E, Dupuits C, et al. Reversible lactic acidosis in a newborn with thiamine transporter-2 deficiency. Pediatrics 2013; 131: e1670-5.
10. Tabarki B, Al-Shafi S, Al-Shahwan S, Azmat Z, Al-Hashem A, Al-Adwani N, et al. Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology 2013; 80: 261-7.
11. Yamada K, Miura K, Hara K, Suzuki M, Nakanishi K, Kumagai T, et al. A wide spectrum of clinical and brain MRI findings in patients with SLC19A3 mutations. BMC Med Genet 2010; 11: 171.
12. Zeng WQ, Al-Yamani E, Acierno JS Jr, Slaugenhaupt S, Gillis T, MacDonald ME, et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet 2005; 77: 16-26.